Elanco Animal Health Incorporated (ELAN)
Automate Your Wheel Strategy on ELAN
With Tiblio's Option Bot, you can configure your own wheel strategy including ELAN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELAN
- Rev/Share 9.0294
- Book/Share 13.6428
- PB 1.5693
- Debt/Equity 0.6213
- CurrentRatio 2.5963
- ROIC 0.0123
- MktCap 10636781360.0
- FreeCF/Share 0.7149
- PFCF 29.9628
- PE 24.4982
- Debt/Assets 0.3063
- DivYield 0
- ROE 0.0674
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ELAN | JP Morgan | Neutral | Overweight | -- | $24 | Oct. 7, 2025 |
| Upgrade | ELAN | Leerink Partners | Market Perform | Outperform | -- | $18 | July 17, 2025 |
| Upgrade | ELAN | William Blair | Market Perform | Outperform | -- | -- | June 26, 2025 |
| Initiation | ELAN | UBS | -- | Buy | -- | $18 | Dec. 9, 2024 |
| Downgrade | ELAN | Morgan Stanley | Overweight | Equal Weight | $17 | $15 | Sept. 19, 2024 |
News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation
Published: April 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
Published: April 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal Health (ELAN) Soars 12.6%: Is Further Upside Left in the Stock?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Elanco Animal Health (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation
Published: April 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Shareholders to Learn More About the Investigation
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff
Published: February 25, 2025 by: Benzinga
Sentiment: Neutral
On Tuesday, Elanco Animal Health Incorporated ELAN reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a reported basis or a 4% organic constant currency growth, beating the consensus of $1.01 billion.
Read More
Elanco Animal Health Incorporated (ELAN) Q4 2024 Earnings Call Transcript
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Elanco Animal Health Incorporated (NYSE:ELAN ) Q4 2024 Earnings Conference Call February 25, 2024 8:00 AM ET Company Participants Tiffany Kanaga - Head of IR Jeffrey Simmons - President & CEO Todd Young - EVP & CFO Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Daniel Clark - Leerink Partners Andrea Alfonso - UBS Erin Wright - Morgan Stanley Balaji Prasad - Barclays Mike DiFiore - Evercore ISI Chris Schott - JPMorgan David Westenberg - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health's Fourth Quarter 2024 Earnings …
Read More
Elanco to Participate in Upcoming Investor Conferences
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
GREENFIELD, Ind. , Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Read More
About Elanco Animal Health Incorporated (ELAN)
- IPO Date 2018-09-20
- Website https://www.elanco.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Jeffrey N. Simmons
- Employees 9000